X

Articles

27Jul

Bio-Rad Geenius HIV 1/2 Implementation

0 Comments | | Return |

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

CTS Charlotte Implements New Laboratory Information System

On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...

Read More >

Update on the Ortho Conversion

At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...

Read More >

Reminder- Check flights and cargo hours for the 4th of July Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Reminder- ZIKV Testing Strategy Webinar Wednesday 8/15/18

Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...

Read More >

Shipping conditions for Monolisa anti-HBs EIA

After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...

Read More >

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 conva...

Read More >

Subscribe here to receive CTS updates!

Name